Teresa A Zimmers

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Michael C. Ostrowski · 6 shared papers, 1 shared grant, 2015–2025 · strength 1.47
   • Grant Project 3 – Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC P01CA236778↗
   • Paper Pancreatic Cancer Induces Population-Specific Switching of Myosin Isoforms and Discrete Activation of Cachexia Genes in… DOI 10.1101/2025.09.01.673500↗
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
2. Ashok Narasimhan · 6 shared papers, 2020–2025 · strength 0.88
   • Paper Transcriptome and microRNAome profiling of human skeletal muscle in pancreatic cancer cachexia DOI 10.1101/2025.09.02.25334959↗
   • Paper Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. DOI 10.1002/jcsm.12998↗
   • Paper Gemcitabine plus nab-paclitaxel preserves skeletal and cardiac mass and function in a murine model of pancreatic cancer… DOI 10.1101/2023.04.15.536434↗
3. Xiaoling Zhong · 7 shared papers, 2015–2025 · strength 0.84
   • Paper Transcriptome and microRNAome profiling of human skeletal muscle in pancreatic cancer cachexia DOI 10.1101/2025.09.02.25334959↗
   • Paper Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. DOI 10.1002/jcsm.12998↗
   • Paper Gemcitabine plus nab-paclitaxel preserves skeletal and cardiac mass and function in a murine model of pancreatic cancer… DOI 10.1101/2023.04.15.536434↗
4. Denis C. Guttridge D · 5 shared papers, 2018–2025 · strength 0.82
   • Paper Pancreatic Cancer Induces Population-Specific Switching of Myosin Isoforms and Discrete Activation of Cachexia Genes in… DOI 10.1101/2025.09.01.673500↗
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
5. Rosalie C. Sears · 3 shared papers, 2025–2026 · strength 0.78
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
   • Paper Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic … DOI 10.1172/jci.insight.192814↗
   • Paper MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia. DOI 10.1158/2767-9764.crc-25-0414↗
6. Martin John Romeo · 1 shared paper, 1 shared grant, 2022–2025 · strength 0.72
   • Grant Project 3 – Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC P01CA236778↗
   • Paper STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. DOI 10.26508/lsa.202201460↗
7. Katherine R. Pelz · 3 shared papers, 2025 · strength 0.66
   • Paper MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia. DOI 10.1158/2767-9764.crc-25-0414↗
   • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
   • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
8. Brittany R. Counts · 3 shared papers, 2023–2025 · strength 0.63
   • Paper Transcriptome and microRNAome profiling of human skeletal muscle in pancreatic cancer cachexia DOI 10.1101/2025.09.02.25334959↗
   • Paper Pancreatic Cancer Induces Population-Specific Switching of Myosin Isoforms and Discrete Activation of Cachexia Genes in… DOI 10.1101/2025.09.01.673500↗
   • Paper Gemcitabine plus nab-paclitaxel preserves skeletal and cardiac mass and function in a murine model of pancreatic cancer… DOI 10.1101/2023.04.15.536434↗
9. Jian Ouyang · 1 shared grant, 2025 · strength 0.61
   • Grant Project 3 – Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC P01CA236778↗
10. Denis C Guttridge · 1 shared grant, 2025 · strength 0.61
    • Grant Project 3 – Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC P01CA236778↗
11. Leonidas G. Koniaris · 1 shared grant, 2025 · strength 0.61
    • Grant Project 3 – Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC P01CA236778↗
12. Safi Shahda · 5 shared papers, 2018–2022 · strength 0.53
    • Paper Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. DOI 10.1002/jcsm.12998↗
    • Paper Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based… DOI 10.3390/cancers12123787↗
    • Paper Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Conver… DOI 10.3390/cancers13081975↗
13. Jonathan Robert Brody · 2 shared papers, 2025–2026 · strength 0.52
    • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
    • Paper MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia. DOI 10.1158/2767-9764.crc-25-0414↗
14. Yunlong Liu · 4 shared papers, 2019–2022 · strength 0.44
    • Paper Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. DOI 10.1002/jcsm.12998↗
    • Paper Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. DOI 10.1084/jem.20190450↗
    • Paper Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Conver… DOI 10.3390/cancers13081975↗
15. Susann Theile · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
16. Dorte Lisbet Nielsen · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
17. Julia Sidenius Johansen · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
18. Olav Faisal Dajani · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
19. Inna Markovna Chen · 2 shared papers, 2025 · strength 0.41
    • Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
    • Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
20. Joshua K. Kays · 3 shared papers, 2018–2021 · strength 0.30
    • Paper Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based… DOI 10.3390/cancers12123787↗
    • Paper Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Conver… DOI 10.3390/cancers13081975↗
    • Paper Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. DOI 10.1002/jcsm.12307↗
21. Gregory B. Lesinski · 4 shared papers, 2015–2022 · strength 0.29
    • Paper STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. DOI 10.26508/lsa.202201460↗
    • Paper Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer… DOI 10.1002/jcsm.12251↗
    • Paper IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. DOI 10.1136/gutjnl-2016-311585↗
22. Parham Diba · 1 shared paper, 2026 · strength 0.26
    • Paper Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic … DOI 10.1172/jci.insight.192814↗
23. Aaron J. Grossberg · 1 shared paper, 2026 · strength 0.26
    • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
24. Jennifer M. Finan · 1 shared paper, 2026 · strength 0.26
    • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
25. Kyle P. Gribbin · 1 shared paper, 2026 · strength 0.26
    • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.